Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CETP | P11597 | 3/20 | 0.47 |
| ▸ | GMNN | O75496 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.47 |
| ▸ | CCR6 | P51684 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28709594 | 0.98 | MEN1 (0.57) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL4751225 | 0.91 | MEN1 (0.50) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL852481 | 0.86 | MEN1 (0.41) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL22653991 | 0.86 | MEN1 (0.41) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL28237365 | 0.82 | MEN1 (0.55) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL27669672 | 0.80 | MEN1 (0.63) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL29083515 | 0.79 | MEN1 (0.52) | MEN1KMT2ACYP3A4SPHK2SPHK1 | |
| SCHEMBL2121177 | 0.79 | MEN1 (0.52) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL2121174 | 0.79 | MEN1 (0.52) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL2839828 | 0.78 | MEN1 (0.52) | MEN1KMT2ACYP3A4PTGS1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999754-B2 | Ruthenium complexes and their use in olefin metathesis reactions | APEIRON SYNTHESIS S.A. (PL) | 2024-06-04 | — | — | US | disclosed |
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | PROVID PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| US-11976085-B2 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis | Aperion Synthesis S.A. (PL) | 2024-05-07 | — | — | US | disclosed |
| US-20240136527-A1 | Binder for Secondary Battery, Negative Electrode for Secondary Battery Including the Same, and Lithium Secondary Battery Including the Same | SK INNOVATION CO., LTD. (KR) | 2024-04-25 | — | — | US | disclosed |
| EP-4354555-A1 | BINDER FOR SECONDARY BATTERY, NEGATIVE ELECTRODE FOR SECONDARY BATTERY INCLUDING THE SAME, AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | SK Innovation Co., Ltd. (KR) | 2024-04-17 | — | — | EP | disclosed |
| CN-117878320-A | Binder for secondary battery, negative electrode for secondary battery comprising same, and lithium secondary battery comprising same | SK新技术株式会社 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024069256-A1 | TRANSITION METAL COMPOUND, CATALYST COMPOSITION COMPRISING THE SAME, AND METHOD FOR PREPARING OLEFIN POLYMER USING THE SAME | SABIC SK NEXLENE COMPANY PTE. LTD. (SG) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024052871-A1 | NOVEL RUTHENIUM COMPLEXES, METHOD OF THEIR SYNTHESIS, INTERMEDIATE COMPOUNDS USED IN THIS METHOD, METHOD OF THEIR SYNTHESIS AND USE OF NOVEL RUTHENIUM COMPLEXES IN OLEFIN METATHESIS REACTIONS | UNIWERSYTET WARSZAWSKI (PL) | 2024-03-14 | — | — | WO | disclosed |
| US-20240076308-A1 | PROCESS FOR PRODUCING RUTHENIUM COMPLEXES AND INTERMEDIATES THEREOF AND THEIR USE IN OLEFIN METATHESIS | APEIRON SYNTHESIS SA (PL) | 2024-03-07 | — | — | US | disclosed |
| CN-117624914-A | Asphalt composition containing property improving additive, asphalt mixture containing asphalt composition and preparation method of asphalt mixture | SK新技术株式会社 | 2024-03-01 | — | — | CN | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2004009609-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004002983-A2 | THERAPEUTIC PIPERAZINE DERIVATIVES USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003105774-A2 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | HLA-DRB1, HLA-B, HLA-C | MEN1 2241/4885KMT2A 1645/4885CYP3A4 1810/4885 |
| US-11976085-B2 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis | POR, CYP1B1, CYP4F11 | MEN1 834/4885KMT2A 4482/4885CYP3A4 12/4885 |
| US-11999754-B2 | Ruthenium complexes and their use in olefin metathesis reactions | ADH1A, CYP2E1, OPRM1 | MEN1 1142/4885KMT2A 4018/4885CYP3A4 22/4885 |
| US-20240076308-A1 | PROCESS FOR PRODUCING RUTHENIUM COMPLEXES AND INTERMEDIATES THEREOF AND THEIR USE IN OLEFIN METATHESIS | POR, CYP1B1, CYP4F11 | MEN1 834/4885KMT2A 4482/4885CYP3A4 12/4885 |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | CASP5, NLRP3, LITAF | MEN1 3398/4885KMT2A 3800/4885CYP3A4 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.